CA
NZ
UK
AU
IND
US
…
AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company's products include AnteoBind, a metal-ion complex-based activation technology that offers an alternative to conventionally used chemistries for the life sciences industry; AnteoBind NXT solution for the development of diagnostic tests; AnteoBind Micro and Micro Kit, a micro-particle-based assay development and bioseparation; AnteoBind Sub-Micron, Particle-based assay development, and bioseparation; AnteoBind Biosensor, a planar solid phase assay development; Activation Kit Multiplex Microspheres, an immunoassay development; and Nano Kit, a nanoparticle-based lateral flow assay development and bioseparation. It also provides AnteoX, an additive that reinforces battery binders that enhance performance of silicon containing anodes; and Ultranode, an ultra-high silicon anode design to offer high performance for lithium-ion batteries. In addition, the company offers contract services. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
AnteoTech Ltd supplies proprietary surface-chemistry reagents and coatings that bind biomolecules on sensors and diagnostic assays for diagnostics, life-science and industrial coating markets. Long-term growth may be supported by wider adoption of point-of-care and biosensor assays and by licensing or supply agreements, and investors may find its chemistry attractive because it appears positioned to simplify assay development and improve test performance.
Principal risks include commercial execution and scale-up challenges, competition from larger reagent suppliers, variable customer adoption of new chemistries and regulatory or quality constraints that could limit revenue growth.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -7.52M | -6.76M | -8.88M | -12.65M | -10.72M |
| Net income | -4.93M | -6.76M | -8.88M | -12.65M | -10.72M |
| Selling general administrative | - | 7.39M | 5.31M | 5.14M | 5.75M |
| Selling and marketing expenses | - | 0.64M | 0.61M | 1.74M | 1.98M |
| Gross profit | - | 0.97M | 0.46M | 0.37M | 0.76M |
| Reconciled depreciation | - | 1.12M | 1.04M | 1.00M | 0.61M |
| Ebit | -7.50M | -9.08M | -12.61M | -10.79M | -13.34M |
| Ebitda | -6.38M | -7.96M | -11.57M | -9.79M | -12.73M |
| Depreciation and amortization | 1.12M | 1.12M | 1.04M | 1.00M | 0.61M |
| Operating income | -7.50M | -8.13M | -12.77M | -10.13M | -10.72M |
| Other operating expenses | 7.97M | 9.09M | 12.19M | 13.06M | 11.48M |
| Interest expense | 0.09M | 0.06M | 0.04M | - | 0.00M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.06M | 0.05M | 0.04M | 0.00M |
| Net interest income | - | -0.01M | 0.01M | 0.01M | 0.00M |
| Extraordinary items | - | - | - | 0.00M | 0.00M |
| Income tax expense | -2.59M | -2.39M | -3.77M | 2.52M | -0.61M |
| Total revenue | 0.47M | 0.97M | 0.46M | 0.37M | 0.76M |
| Total operating expenses | 6.84M | 9.09M | 12.19M | 13.72M | 14.10M |
| Total other income expense net | -0.02M | 1.37M | 3.89M | 0.66M | 2.01M |
| Net income from continuing ops | - | -6.76M | -8.88M | -12.65M | -10.72M |
| Net income applicable to common shares | - | -6.76M | -8.88M | -12.65M | -10.72M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 15.40M | 6.45M | 9.38M | 5.36M | 15.26M |
| Other current assets | 0.21M | 0.30M | 0.22M | 0.22M | 0.25M |
| Total liab | 3.60M | 3.30M | 4.08M | 2.99M | 2.91M |
| Total stockholder equity | 11.80M | 3.15M | 5.31M | 2.38M | 12.36M |
| Other current liab | 0.61M | 0.50M | 0.65M | 1.27M | 0.91M |
| Common stock | 116.83M | 103.78M | 99.82M | 89.30M | 87.45M |
| Capital stock | - | 103.78M | - | 89.30M | 87.45M |
| Retained earnings | -111.58M | -106.66M | -99.90M | -91.02M | -78.36M |
| Other liab | - | - | - | 0.52M | 0.52M |
| Other assets | - | - | - | 0.00M | 0.42M |
| Cash | 5.70M | 2.34M | 5.03M | 2.72M | 10.10M |
| Total current liabilities | 1.43M | 1.31M | 1.79M | 1.80M | 1.62M |
| Current deferred revenue | - | - | - | -0.65M | -0.26M |
| Net debt | -3.55M | -0.38M | -2.69M | -1.41M | -9.07M |
| Short term debt | 0.56M | 0.55M | 0.63M | 0.65M | 0.26M |
| Short long term debt | - | 0.00M | - | - | - |
| Short long term debt total | 2.15M | 1.96M | 2.33M | 1.31M | 1.03M |
| Other stockholder equity | - | - | - | 4.09M | -9.09M |
| Property plant equipment | - | - | - | 2.22M | 4.02M |
| Total current assets | 11.55M | 2.73M | 5.45M | 3.14M | 10.83M |
| Long term investments | - | 0.36M | - | - | - |
| Net tangible assets | - | - | - | 2.38M | 12.36M |
| Short term investments | 5.50M | - | - | - | - |
| Net receivables | 0.13M | 0.09M | 0.21M | 0.20M | 0.47M |
| Long term debt | - | 0.01M | - | - | - |
| Accounts payable | 0.25M | 0.26M | 0.52M | 0.53M | 0.70M |
| Accumulated other comprehensive income | 6.55M | 6.03M | 5.39M | 4.09M | 3.26M |
| Non currrent assets other | - | - | - | -2.22M | 0.42M |
| Non current assets total | 3.85M | 3.72M | 3.93M | 2.22M | 4.44M |
| Capital lease obligations | - | 1.94M | - | 1.31M | 1.03M |
| Long term debt total | - | - | - | 0.66M | 0.78M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -0.17M | -1.06M | -0.69M | -3.12M |
| Change to liabilities | - | - | - | -0.16M | 0.36M |
| Total cashflows from investing activities | -5.55M | -0.17M | -1.06M | -0.69M | -3.12M |
| Net borrowings | - | -0.00M | - | -0.46M | -0.28M |
| Total cash from financing activities | 12.45M | 3.32M | 9.89M | 1.39M | 0.48M |
| Change to operating activities | - | - | - | 0.07M | 0.20M |
| Net income | -4.93M | -6.76M | -8.88M | -12.65M | -10.72M |
| Change in cash | 3.36M | -2.68M | 2.31M | -7.38M | -11.29M |
| Begin period cash flow | 2.34M | 5.03M | 2.72M | 10.10M | 21.39M |
| End period cash flow | 5.70M | 2.34M | 5.03M | 2.72M | 10.10M |
| Total cash from operating activities | -3.53M | -5.83M | -6.52M | -8.08M | -8.69M |
| Issuance of capital stock | - | 3.96M | 10.52M | 1.85M | 0.76M |
| Depreciation | 1.12M | - | 1.04M | 1.00M | 0.61M |
| Other cashflows from investing activities | - | 0.05M | - | - | - |
| Change to account receivables | - | 0.12M | 0.04M | 0.27M | -0.23M |
| Sale purchase of stock | - | 3.96M | 10.52M | - | 0.76M |
| Other cashflows from financing activities | -0.60M | -0.64M | -0.63M | -0.46M | -0.28M |
| Change to netincome | - | - | - | 3.39M | 1.24M |
| Capital expenditures | 0.05M | 0.22M | 1.06M | 0.69M | 3.12M |
| Change in working capital | - | -0.79M | 0.06M | 0.27M | -0.23M |
| Stock based compensation | - | - | 1.29M | 0.83M | 1.20M |
| Other non cash items | 0.27M | -5.03M | -0.03M | 3.57M | 1.42M |
| Free cash flow | -3.58M | -6.05M | -7.58M | -8.77M | -11.81M |
Sector: Basic Materials Industry: Specialty Chemicals
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADO Anteotech Ltd |
-0.00 11.11% |
0.02 | - | 10.50 | 125.69 | 4.15 | 85.38 | -4.53 |
| ORI Orica Ltd |
-0.42 1.83% |
22.50 | 44.94 | 16.18 | 1.30 | 2.74 | 1.57 | 10.83 |
| DNL Dyno Nobel Ltd |
-0.11 2.80% |
3.82 | 28.07 | 21.10 | 1.76 | 1.65 | 2.17 | 10.94 |
| DGL DGL Group Ltd |
0.02 8.33% |
0.26 | - | 13.37 | 0.15 | 0.23 | 0.52 | 34.58 |
| CXL CALIX Ltd |
0.04 16.28% |
0.25 | - | - | 1.41 | 1.18 | 1.10 | -54.23 |
AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company's products include AnteoBind, a metal-ion complex-based activation technology that offers an alternative to conventionally used chemistries for the life sciences industry; AnteoBind NXT solution for the development of diagnostic tests; AnteoBind Micro and Micro Kit, a micro-particle-based assay development and bioseparation; AnteoBind Sub-Micron, Particle-based assay development, and bioseparation; AnteoBind Biosensor, a planar solid phase assay development; Activation Kit Multiplex Microspheres, an immunoassay development; and Nano Kit, a nanoparticle-based lateral flow assay development and bioseparation. It also provides AnteoX, an additive that reinforces battery binders that enhance performance of silicon containing anodes; and Ultranode, an ultra-high silicon anode design to offer high performance for lithium-ion batteries. In addition, the company offers contract services. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
Brisbane Technology Park, Eight Mile Plains, QLD, Australia, 4113
61 7 3219 0085
| Name | Title | Year Born |
|---|---|---|
| Mr. Timothy J. Pritchard B.Bus, CPA, GIA (Cert), MCom, MIT | CFO & Company Sec. | NA |
| Mr. Christopher Parker | Chair of the Clinical Advisory Board & Non Exec. Director | NA |
| Mr. David John Radford BSc (Hons), MAICD, MBA | MD, CEO & Director | NA |
| Dr. N. Joe Maeji B.Sc., Ph.D. | Founder & Chief Scientific Officer | NA |
| Ms. Katrina Byrne | Chief Operating Officer | NA |
| Ms. Friederike Graser | Communications Mang. | NA |
| Dr. Charlie Huang B.Sc., Ph.D. | Chief Innovation Officer | NA |
| Mr. Selahattin Guldu | Exec. VP of Commercial Banking | NA |
| Mr. Manuel Wieser | Head of Energy | NA |
| Mr. Pierre Nathie | Head of Products & Services ? Life Sciences | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...